Mono- and dual-agonist compounds of human GLP1r and GIPR for obesity & t2dm
CA3327875A1Undetermined Publication Date: 2025-10-30PROTAGONIST THERAPEUTICS INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- CA3327875
- Authority / Receiving Office
- CA · CA
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-04-17
- Filing Date
- 2025-04-17
- Publication Date
- 2025-10-30
Abstract
The present disclosure relates to peptide compounds which are mono- or dual-agonists of the human glucagon-like peptide- 1 (GLP-1) receptor (GLP1R) and the human glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR). The invention also relates to peptide compounds that are suitable for oral administration. Thes peptide compounds of the invention may be useful in the treatment of type 2 diabetes mellitus (T2DM) and obesity.
Need to check novelty before this filing date? Find Prior Art
